Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03860376 · ClinicalTrials.gov registry record
Ex Vivo Drug Sensitivity Testing and Mutation Profiling
A clinical trial, sponsored by Florida International University.
- Completed
- Registry status
- 25
- Enrollment target
NCT03860376 is a clinical trial that has completed, run by Florida International University. The registered enrollment target is 25 participants.
The verdict
NCT03860376 has completed, sponsored by Florida International University.
- COMPLETED
- Registry status
- 25 participants
- Enrollment target
Study Summary
This study is a prospective, non-randomized feasibility study. Freshly isolated tumor cells from patients will be screened using state-of-the-art viability assay designed for ex vivo high-throughput drug sensitivity testing (DST). In addition, genetic information will be obtained from cancer and normal (germline) tissue and correlated with drug response. This study will provide the platform for informing treating physician about individualized treatment options. The main outcome of this study will be the proportions of the patients whose treatment was guided by the personalized medicine approach.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2019-02-21 |
| Est. Completion | 2022-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03860376
The ClinicalTrials.gov registry entry for NCT03860376 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Florida International University, which has 89 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT03860376 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03860376 about?
NCT03860376 is a clinical study titled "Ex Vivo Drug Sensitivity Testing and Mutation Profiling". This study is a prospective, non-randomized feasibility study. Freshly isolated tumor cells from patients will be screened using state-of-the-art viability assay designed for ex vivo high-throughput drug sensitivity testing (DST). In addition, genetic information will be obtained from cancer and nor...
What is the current status of trial NCT03860376?
This trial is currently completed. The enrollment target is 25 participants. The study started on 2019-02-21. Estimated completion is 2022-12-31.
Who is sponsoring clinical trial NCT03860376?
This trial is sponsored by Florida International University, which has 89 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.